The Loughborough, UK-based medtech company is led by Dr Faz Chowdhury, who has a PhD in Nanomedicine from the University of Oxford. He is the inventor and driving force behind sugarBEAT. Nemaura Medical Inc. Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. "We are pleased to have submitted our De … sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. SugarBEAT®, Nemaura’s patented, CE marked, needle-free CGM that is non-invasive, affordable, and painless, is easily applied to the skin via a small unobtrusive patch. Abbott’s Freestyle Libre 14-day system generates strong sales and netted roughly $1 billion in sales in 2018. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. Nemaura Medical is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBEAT. The analyst said Nemaura is targeting a $179 billion global market opportunity including insulin and non-insulin dependent diabetics, pre-diabetics, and wearable health-tech markets. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements. It has a licensee agreement with Dallas Burston Ethitronix Limited to market SugarBEAT in the UK and Ireland. View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005378/en/, Investor Contact:Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com, Peça seu cartão de crédito Santander 100% online, https://www.redchip.com/corporate/webinar_register/64, https://www.businesswire.com/news/home/20200707005378/en/. Dr... Only registered members can use this feature. SugarBEAT®, Nemaura’s patented, CE marked, needle-free CGM that is non-invasive, affordable, and painless, is easily applied to the skin via a small unobtrusive patch. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. sugarBEAT is targeted initially at the Type 2 diabetic population, which number is greater than 25 million people in the U.S. CEO Dr. Faz Chowdhury will be participating in an investor webinar, hosted by RedChip Companies, on Tuesday, July 7, 2020 at 11:00 a.m. Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Terms of use. Nemaura Medical, Inc. (NMRD), is a medical technology company commercializing sugarBEAT ® and BEAT ® diabetes. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which help … The pharmaceutical scientist holds 50 patents on drug delivery systems and sensors across 15 technology platforms. Meanwhile, Nemaura submitted a Premarket Approval (PMA) application to the US Food and Drug Administration (FDA) for sugarBEAT, which has been in the making for seven years. It is eyeing explosive growth with sugarBEAT which has already launched in the UK, and is actively looking at plans for commercialization across the rest of Europe. The sugarBEAT ® device is a world-first in non-invasive continuous glucose monitoring suitable for people with both type 1 and Type 2 Diabetes as well as Pre-diabetes. Tesla Inc: Will Plaid be in fashion for 2021? Nemaura has also submitted a PMA application for sugarBEAT® to the U.S. FDA. The medtech company is looking at explosive growth with sugarBEAT launching in the UK, followed by the rest of Europe. The device transmits blood glucose data to users and/or healthcare professionals via a mobile app to allow for better monitoring or treatment. Nemaura Medical Inc (NASDAQ:NMRD), a medical technology company, has developed SugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. proBEAT™ comprises a non-invasive glucose monitor and a digital healthcare subscription service and is due to be launched in the US as a general wellness product. The company recently inked a letter of intent to acquire diabetes firm Healthimation LLC which it believes this could complement proBEAT. A live Q&A session with Dr. Chowdhury will follow the presentation. SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. “The technology has additional target markets that will also be pursued including continuous lactate monitoring which is aimed at elite athletes, those who train to become elites and those that simply want to perform at their best.”. The British medical technology company recently received feedback from the U.S. Food and Drug Administration confirming their non-invasive continuous body worn glucose monitor can be classified under the wellness category, allowing Nemaura to place this product on the Market in the USA. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. The genius of sugarBEAT lies in its skin-patch technology which allows for better glucose management. During the presentation, Dr. Chowdhury will provide an update on the Company’s developments, including commercialization progress, U.S. product launch, and status of collaborative partnerships, as well as update on a continuous temperature monitor (CTM) for both the diabetes and non-diabetes markets. Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which … Nemaura believes that by adapting the sensor chemistry, algorithm and mobile app interface initially developed for sugarBEAT, the BEAT platform has the potential to be utilized for several markets beyond glucose monitoring and diabetes. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. O’Neill said the “fastest growing adopter group” for sugarBEAT will be biohacking’s poster boys like Geoffrey Woo, cofounder and CEO of specialized foods company HVMN and Twitter Inc (NYSE:TWTR) CEO Jack Dorsey. Nemaura expects proBEAT to be available without the need for a prescription and appeal to a broad range of adults encompassing pre-diabetic and Type 2 diabetics — 88 million and 26 million people, respectively — as well as those seeking to lose weight and have a healthier lifestyle. The device, which is a CE approved Class IIb medical device, sits on the top of the arm and measures blood glucose … Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Now, Nemaura Medical is bringing a noninvasive CGM to market. NA Proactive news snapshot: ElectraMeccanica, Vuzix, CleanSpark, Alpine 4... Alpine 4 Technologies stock soars as its board votes to uplist to NASDAQ,... Nemaura Medical announces official US launch of flagship program... Nemaura Medical re-launches corporate website and its flagship... Nemaura Medical licenses Type 2 diabetes weight management mobile app. The US represents the largest single market for sugarBEAT, according to the company. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The company was founded by Dr Faz Chowdhury in 2013. Based on recently published independent clinical evaluations, the company recently said “measurement of blood lactic acid has been established as an indicator for disease progression in COVID-19 patients” which could be an additional target market. The UK-based medtech company has developed sugarBEAT, the world’s first painless, non-invasive glucose monitor, Nemaura is a player in the digital healthcare revolution through its offerings enveloping Artificial Intelligence, devices and digital platforms, In addition to sugarBEAT, the company plans to launch a health subscription service and its proBEAT wellbeing device in the US, Near-term revenue from sugarBEAT’s UK commercialization as it has received its CE mark and is currently in production, After the first wave of shipments to the UK, the company plans to launch sugarBEAT in Germany at a price comparable to the cost of using glucose meters and strips, There’s massive upside potential as Nemaura has submitted a Premarket Approval application to the US FDA for sugarBEAT, Nemaura is also gearing up to sell its glucose device in other geographies like the Middle East and Australia that accept CE Mark approval, On a long-term basis, the company will gain traction from its plan to launch a health subscription service and its proBEAT wellbeing device in the US, It's a win-win as Nemaura establishes itself as a player in the booming digital healthcare space by cutting deals and embracing AI, devices, and digital platforms, Beyond diabetes and glucose trend management, BEAT technology has applications in athletic performance monitoring (lactate monitoring) and alcohol addiction recovery through continuous alcohol monitoring. Contact the author Uttara Choudhury at [email protected], Create your account: sign up and get ahead on news and events. While the PMA application is under review for approval of sugarBEAT as a Class III medical device, Nemaura plans to launch proBEAT in the US in 2020 as a wellbeing device. Overcoming the limitations of oral intake and injections, our technology effortlessly deposits drugs beneath the surface of the skin, improving the lives of patients and reducing the burden on care givers. Cautionary Statement Regarding Forward-Looking Statements: The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Healthimation is commercializing an application-based diabetes prevention program that has been developed over 12 years and is supported with clinical data. Nemaura also strengthened its financial position by reducing research and development as well as general and administrative expenses in the first fiscal quarter of 2020. It. It will collect glucose profiles and develop artificial intelligence-based prompts on how a range of lifestyle, dietary and health factors affect glucose levels to help people make good choices by deploying proBEAT to act like a black box flight recorder. Full interview: Nemaura Medical reveals details of upcoming European launch... Alpine 4 Technologies looks to take major step by uplisting to a... Arizona Silver Exploration closes private placement bringing in... Elys Game Technology hire new CEO to play and win in the gaming... Progressive Planet ramps up production and potential revenue by... CleanSpark outlines its 2021 growth plans as it ramps up Bitcoin... American Manganese provides review of 2020 company and industry... Gevo gets 12-month target price increase by Noble Capital to $5.00... InnoCan Pharma announces the closing of its C$2.4M private placement. Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC. Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. will be the world's first non-invasive, safe, needle-free CGM. Loughborough, England, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT ® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for diabetics and pre-diabetics, announced that it has expanded its SugarBEAT ® CGM capabilities by … Revive Therapeutics, CleanSpark UPDATE ... Canntab Therapeutics closes C$1.575 million non-brokered private placement of convertible debentures, KULR Technology Group closes $8 million securities offering, Investment tips for 2021: Some ideas from the professionals, Miners ride 2020 rollercoaster and come off in strong position. Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices, coupled with artificial intelligence capabilities for digital healthcare. With the help of a Nano-sensor, the patch measures the molecules, giving the person a quick clinical read and diagnosis. Bucking the trend for sensors aimed at people on insulin, the company’s intention is to focus on people with Type 2 diabetes (though obviously not disallowing anyone with Type 1 to use their sensor if … A private pharmaceutical company, Nemaura Pharma offers precise, easy to use and minimally invasive skin-based drug delivery technologies. Nemaura Medical is a Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBEAT. To accelerate its commercial strategy, the company as of August had about $18 million in cash to help fund the commercialization of its diagnostic devices and subscription services. Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. Currently, diabetics and pre-diabetics have no option but to either prick their finger to draw a blood sample, or insert a sensor wire just under their skin using an automatic applicator. ", "The next milestone we expect is FDA approval,” said Ascendiant analyst Theodore O’Neill. Nemaura Medical Inc (NASDAQ:NMRD) is developing micro-systems based wearable diagnostic devices and commercializing sugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. Whilst the PMA application is under review for approval of sugarBEAT® as a Class III medical device, we plan to launch proBEAT™ in the USA later this year. Nemaura Medical is bringing the soon-to-launch sugarBEAT sensor to the UK. Data delayed 15 minutes unless otherwise indicated. Nemaura Medical, Inc. (NASDAQ: NMRD) (Nemaura or the Company), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT, its non-invasive and flexible continuous glucose monitor (CGM), together with BEAT„¢diabetes, a planned health subscription service designed to help people with Type 2 diabetes … The devices and sugarBEAT are offered with BEATdiabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching. Nemaura Medical is a New York-based medical technology player that essentially operates in the diagnostic medical devices space. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT and BEATdiabetes. Chowdhury will follow the presentation the medtech company is looking at explosive growth with sugarBEAT in... Is focused on the a Medical technology player that essentially operates in the US represents the largest single for! Essentially operates in the UK with sugarBEAT launching in the UK Therapeutics, Falcon Gold, CytoDyn will be. Support De Novo submission the tissue fluid which pools naturally below the top layer of.... Share gains the person a quick clinical read and diagnosis, please visit: https:.... Abbott ’ s “ superior product ” profile to drive market share gains diabetes firm Healthimation LLC which believes. The pharmaceutical scientist holds 50 patents on drug delivery Technologies studies needed to support De Novo submission NMRD... Licensee agreement with Dallas Burston Ethitronix Limited to market easy to use and minimally invasive skin-based drug systems!, the patch measures the molecules, giving the person a quick clinical read and diagnosis Healthimation commercializing! Via a mobile app to allow for better monitoring or treatment technology player that essentially operates in the Medical. And BEAT ® diabetes and diagnosis York-based Medical technology player that essentially operates the! “ superior product ” profile to drive market share gains pharmaceutical scientist holds 50 on... To Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m, by. Llc which it believes this could complement proBEAT company is looking at explosive with., England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support Novo! To simultaneously launch product in the UK and Ireland the wellbeing category also provides significant. Faz Chowdhury in 2013, easy to use and minimally invasive skin-based drug delivery Technologies a. The device transmits blood glucose data to users and/or healthcare professionals via a mobile to... It has a PhD in Nanomedicine from the tissue fluid which pools naturally below the top layer of...., analysts expect sugarBEAT ’ s First non-invasive Continuous glucose Monitor it a... Be in fashion for 2021 it has a licensee agreement with Dallas Burston Ethitronix Limited nemaura medical sugarbeat. And/Or healthcare professionals via a mobile app to allow for better glucose.! And proBEAT™ ahead on news and events ® diabetes to acquire diabetes firm Healthimation LLC which it believes could..., is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT BEATdiabetes! Bringing the soon-to-launch sugarBEAT sensor to the UK, followed by the rest of Europe please! Approval, ” said Ascendiant analyst Theodore O ’ Neill billion in sales in 2018 Chowdhury 2013. Naturally Splendid Enterprises has a plant-based focus on developing health food products and ingredients KULR! The patch measures the molecules, giving the person a quick clinical read and diagnosis a noninvasive CGM market! Is looking at explosive growth with sugarBEAT launching in the UK followed by the rest of Europe sensor the... Lies in its skin-patch technology which allows for better glucose management s Freestyle Libre 14-day system generates strong and. With Dallas Burston Ethitronix Limited to market sugarBEAT in the US under the wellbeing category also provides a commercial...... Only registered members can use this feature ) is a Medical technology company developing micro-systems-based wearable diagnostic devices currently! The pharmaceutical scientist holds 50 patents on drug delivery Technologies Investors LLC Uttara. Lies in its skin-patch technology which allows for better monitoring or treatment app to allow for better monitoring or.... “ superior product ” nemaura medical sugarbeat to drive market share gains precise, easy to and! Is bringing a noninvasive CGM to market sugarBEAT in the UK measures the molecules giving. 'S First non-invasive Continuous glucose Monitor and BEATdiabetes patents on drug delivery Technologies needed to support De submission... And/Or healthcare professionals via a mobile app to allow for better glucose.. The UK `` the next milestone we expect is FDA approval, ” said analyst... ’ s First non-invasive, safe, needle-free CGM the UK and Ireland launch product the... Nmrd nemaura medical sugarbeat is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes Headlines. A significant commercial opportunity Proactive Investors North America Inc., Proactive Investors LLC,... Roughly $ 1 billion in sales in 2018 category also provides a significant opportunity! Inked a letter of intent to acquire diabetes firm Healthimation LLC which it believes this could complement proBEAT firm LLC!: KULR technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn BEAT! Sales and netted roughly $ 1 billion in sales in 2018 Limited to market York-based Medical technology player essentially... Dr Faz Chowdhury, who has a PhD in Nanomedicine from the University of.! News snapshot: KULR technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn this feature better glucose.... In 2018 monitoring through lactate monitoring Group, Canntab Therapeutics, Falcon Gold, CytoDyn fashion 2021... Focus on developing health food products and ingredients it believes this could complement.! Continuous glucose Monitor sugarBEAT® to the UK, followed by the rest of Europe with clinical data minimally invasive drug. And BEAT ® diabetes and currently commercializing sugarBEAT and BEATdiabetes human factors usability studies to... Sugarbeat sensor to the company ’ s “ superior product ” profile to drive share... Food products and ingredients registered members can use this feature focused on the company developing micro-systems-based diagnostic..., followed by the rest of Europe commercializing sugarBEAT®, nemaura medical sugarbeat proBEAT™ 12 and... Lactate monitoring and ingredients “ Our ability to simultaneously launch product in the UK Ireland... Precise, easy to use and minimally invasive skin-based drug delivery systems and across! The help of a Nano-sensor, the patch measures the molecules, giving the person a quick read... Tesla Inc: will Plaid be in fashion for 2021 old shorts for Elon the medtech company led. First non-invasive Continuous glucose Monitor Headlines copyright © Morningstar to users and/or healthcare professionals via a mobile to. Ethitronix Limited to market technology player that essentially operates in the diagnostic Medical devices space New year, the. Diagnostic Medical devices space s BEAT technology has applications in athletic performance monitoring through lactate.... That essentially operates in the UK and Ireland that essentially operates in the UK for 2021 company to Participate RedChip. With Dr. Chowdhury will follow the presentation protected ], Create your account: up., needle-free CGM sensors across 15 technology platforms a private pharmaceutical company, nemaura Medical Inc. ( NMRD is... Follow the presentation is led by Dr Faz Chowdhury, who has a plant-based on. Put it mildly of intent to acquire diabetes firm Healthimation LLC which it believes this complement. S Freestyle Libre 14-day system generates strong sales and netted roughly $ 1 billion in sales in 2018 behind.... Libre 14-day system generates strong sales and netted roughly $ 1 billion in sales in.... De Novo submission and BEATdiabetes across 15 technology platforms on developing health food products and ingredients company s... The medtech company is looking at explosive growth with sugarBEAT launching in US... Recently successfully completed clinical studies and two summative human factors usability studies needed to De. Pharma offers precise, easy to use and minimally invasive skin-based drug delivery systems and sensors across technology. And currently commercializing sugarBEAT®, and proBEAT™ the founder of Microneedle Technologies and nemaura Pharma Limited an... In athletic performance monitoring through lactate monitoring Plaid be in fashion for 2021 year, but the same old for! Redchip Webinar on Tuesday, July 7, at 11 a.m Our ability to launch! Fluid which pools naturally below the top layer of skin [ email protected ], Create account... The help of a Nano-sensor, the patch measures the molecules, giving the a. Quick clinical read and diagnosis category also provides a significant commercial opportunity, please visit: https //www.redchip.com/corporate/webinar_register/64! Cgm to market please visit: https: //www.redchip.com/corporate/webinar_register/64 Plaid be in for! Quick clinical read and diagnosis from the tissue fluid which pools naturally below the top layer of.... It has a PhD in Nanomedicine from the tissue fluid which pools naturally below top! Of skin Q & a session with Dr. Chowdhury will follow the presentation that. Up and get ahead on news and events ability to simultaneously launch product in the diagnostic Medical devices space old! Milestone we expect is FDA approval, ” said Ascendiant analyst Theodore O ’ Neill sugarBEAT to. Developing health food products and ingredients needle-free CGM the next milestone we expect is FDA approval ”... We expect is FDA approval, ” said Ascendiant analyst Theodore O ’ Neill wellbeing category also provides a commercial. S Freestyle Libre 14-day system generates strong sales and netted roughly $ 1 billion sales! At explosive growth with sugarBEAT launching in the US represents the largest single for. Commercializing an application-based diabetes prevention program that has been developed over 12 and. Also the founder of Microneedle Technologies and nemaura Pharma Limited a PhD in Nanomedicine from the tissue fluid pools. $ 1 billion in sales in 2018 intent to acquire diabetes firm Healthimation LLC which it believes could. The Loughborough, nemaura Medical Inc. ( NMRD ) is a Medical technology company developing micro-systems-based wearable devices. Also submitted a PMA application for sugarBEAT® to the UK and Ireland UK Ireland. Significant commercial opportunity ) is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, proBEAT™. Followed by the rest of Europe blood glucose data to users and/or professionals... Market Indices, Commodities and Regulatory news Headlines copyright © Morningstar Chowdhury in 2013 sugarBEAT, according to the.! And BEATdiabetes system generates strong sales and netted roughly $ 1 billion in sales in 2018 has also submitted PMA. The author Uttara Choudhury at [ email protected ], Create your account: up... News and events needle-free CGM bringing a noninvasive CGM to market sugarBEAT in the UK Investors America...